

09/355,214
7-23-99

435/6

435/7.1

AUG 55

CONV 08/819,013

Efile 1-24-97

520/350

CLAIMS

We claim:

1. A recombinant nucleic acid encoding a BLNK protein.
2. A recombinant nucleic acid according to claim 1 that is at least 60% identical to the sequence depicted in Figure 2.
3. A recombinant nucleic acid according to claim 1 wherein said BLNK protein is a human BLNK protein.
4. A recombinant nucleic acid according to claim 1 encoding the amino acid sequence depicted in Figure 1.
5. A recombinant nucleic acid according to claim 1 which will hybridize to the nucleic acid depicted in Figure 2 under high stringency conditions.
6. A recombinant nucleic acid according to claim 1 comprising the nucleic acid depicted in Figure 2.
7. An expression vector comprising transcriptional and translational regulatory DNA operably linked to DNA encoding a BLNK protein.
8. A host cell transformed with the nucleic acid of claim 1.
9. A host cell transformed with an expression vector according to claim 7.
10. A method of producing a BLNK protein comprising:
 - a) culturing a host cell transformed with nucleic acid encoding a BLNK protein; and
 - b) expressing said nucleic acid to produce a BLNK protein.

11. A recombinant BLNK protein.

12. A recombinant BLNK protein according to claim 11 encoded by a nucleic acid which hybridizes to the nucleic acid sequence shown in Figure 2 under high stringency conditions.

13. A recombinant BLNK protein according to claim 11 encoded by a nucleic acid which is at least 60% identical to the nucleic acid sequence shown in Figure 2.

14. A recombinant BLNK protein according to claim 11 which is at least about 50% homologous to the amino acid sequence shown in Figure 1.

15. A recombinant BLNK protein according to claim 11 which has the amino acid sequence shown in Figure 1.

16. A pharmaceutical composition comprising a BLNK protein.

17. A polypeptide capable of specifically binding to a BLNK 1 protein.

18. A polypeptide according to claim 17 wherein said polypeptide is an antibody.

19. An antibody which binds a BLNK protein.

20. A method for detecting a BLNK protein in a target sample comprising contacting a labelled polypeptide according to claim 17 with said target sample and assaying for the presence of binding between said labelled polypeptide and BLNK, if present, in said target sample.

21. A method for screening for a bioactive agent capable of binding to a BLNK protein, said method comprising combining a BLNK protein and a candidate bioactive agent, and determining the binding of said candidate agent to BLNK protein.

22. A method for screening for a bioactive agent capable of modulating the bioactivity of a BLNK protein, said method comprising the steps of:

a) combining:

i) a BLNK protein;

ii) a candidate bioactive agent; and

iii) a protein selected from the group consisting of Grb2 and PLC- γ ; and

b) determining the binding of said protein to said BLNK protein;

wherein the absence of binding of said protein to said BLNK protein indicates that said agent is capable of modulating the bioactivity of said BLNK protein.

add
A1

add
B1

086220 47396640